7:30 am Registration, Coffee & Networking

8:20 am Chair’s Opening Remarks

8:30 am Experiment with Immune Targeting Therapeutics Agents & Synthetic Mouse Model

The Changing Expectations of Model Requirements

8:55 am Developing Human Target Knock-In Mouse Models for Immuno-Oncology Drug Discovery

9:20 am Opportunities & Challenges in Utilizing Humanized Mice to Model Human T Cell Responses

  • Mike Brehm Professor , University of Massachusetts

9:45 am Addressing the Demand for Clinically Relevant Models in IO Research

  • Rick Huntress Director of Commercial Business Development , The Jackson Laboratory

10:10 am Panel Discussion – The Changing Expectations of Model Requirements

  • Davy Ouyang Executive Director , Crown Bioscience
  • Mike Brehm Professor , University of Massachusetts
  • Rick Huntress Director of Commercial Business Development , The Jackson Laboratory

10:30 am Speed Networking

11:00 am Morning Refreshments

Advances in Preclinical and Translational Imaging

11.30 Ultrasound Imaging of Patient-Derived Xenograft to Investigate Intratumoral Heterogeneous Response

Fred Roberts, Sales Manager, Fujifilm Visual Sonics


11.45 Characterization of Mouse Syngeneic Tumor Models Using Multiplex T Cell Panel

Omid Ghasemi, Scientist I, Imaging, Takeda


12.10 Using 3D Imaging & AI to Advance Preclinical Cancer Research

Juan Delgado, Lead Data Scientist, Fuel3D


12.25 Using Clearing-Enhanced 3D (Ce3D) to Dissect Tumor Immune Microenvironment in Genetically Egineered Mouse Models

Chen Zhao, Clinical Fellow, National Institutes of Health


12.50 Q&A Panel - Advances in Preclinical & Translational Imaging

Omid Ghasemi, Scientist I, Imaging, Takeda
Chen Zhao, Clinical Fellow, National Institutes of Health

Advancing Biologic Therapeutics

1:10 pm Lunch

Engineering & Targeting the Microenvironment

2.10 Applications of An In-Vitro Multi-Cell Model of the Tumor Microenvironment

Daniel Gioeli, Associate Professor,  University of Virginia


2.35 Attention to Metastasis: Understanding Importance of Tumor Microenvironment In Immunotherapy Development

Jenni Bernoulli, COO, Pharmatest Services


2.50 Targeting Immunosuppression in the Tumor Microenvironment – Modelling Tumor-Immune Interactions In Vitro

Silvia Goldoni, Investigator & Head of Oncology Lab, Novartis


3.15 Q&A Panel – Engineering & Targeting The Microenvironment

Silvia Goldoni, Investigator & Head of Oncology Lab, Novartis
Daniel Gioeli, Associate Professor,  University of Virginia

Novel Models for Novel Targets

3:35 pm Afternoon Refreshments

Modelling Cancer Drug Resistance

4:05 pm Syngeneic Models of Breast and Ovarian Cancers: Effects of Immune Modulatory Agents in Classically “Cold” Tumors

4:30 pm Translational Strategies to Overcome Primary, Acquired & Adaptive Resistance

  • Corinne Reimer Associate Director, In Vivo Pharmacology, AstraZeneca

4:55 pm Capturing Drug-Induced Modulation of the Tumor Microenvironment Using A Personalized Ex Vivo Histoculture Approach

  • Stefan Jellbauer Technical Liaison for Translational Applications , Mitra Biotech

5:20 pm Q&A – Modelling Cancer Drug Resistance

  • Corinne Reimer Associate Director, In Vivo Pharmacology, AstraZeneca
  • Stefan Jellbauer Technical Liaison for Translational Applications , Mitra Biotech

5:50 pm Close of Conference Day One

6:00 pm Evening Drinks Reception & Poster Session Hosted by Crown Biosciences